133 related articles for article (PubMed ID: 32289799)
1. Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Lin T; Wang X; Gao H; Feng Z; Xu L; Ma J; Li Z; Zhang L; Huang R; Liang X; Liu S
Blood Purif; 2020; 49(6):692-699. PubMed ID: 32289799
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
3. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Chevallier E; Büchler M; Caillard S; Bouvier N; Colosio C; Rivalan J; Sayegh J; Bertrand D; Le Meur Y; Thierry A; Garrouste C; Rerolle JP; Rostaing L; Gatault P
Transplant Proc; 2020 Dec; 52(10):3179-3185. PubMed ID: 32636068
[TBL] [Abstract][Full Text] [Related]
4. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Tao T; Jiang X; Chen Y; Song Y
Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
8. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
9. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
Rosenthal ES; Kottilil S; Polis MA
Expert Opin Pharmacother; 2016; 17(5):743-9. PubMed ID: 26898158
[TBL] [Abstract][Full Text] [Related]
11. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A
Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857
[TBL] [Abstract][Full Text] [Related]
12. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
Surendra M; Raju SB; Sridhar N; Vijay Kiran B; Rajesh G; Anvesh G; Raju N
Hemodial Int; 2018 Apr; 22(2):217-221. PubMed ID: 28972699
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Nagaty A; Helmy SH; Abd El-Wahab EW
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Liu CH; Chen YS; Wang SS; Liu CJ; Su TH; Yang HC; Hong CM; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2018 Jan; 66(2):289-292. PubMed ID: 29020359
[TBL] [Abstract][Full Text] [Related]
17. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
Hsu SJ; Enkhzaya S; Lin YY; Tseng TC; Khosbayar T; Tsai CH; Wang TS; Enkhtuya D; Ivshinkhorol D; Naranzul N; Jargalsaikhan B; Amarsanaa J; Baatarkhuu O; Kao JH
J Formos Med Assoc; 2020 Mar; 119(3):712-719. PubMed ID: 31672433
[TBL] [Abstract][Full Text] [Related]
18. Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection.
Havens JP; Regan NN; Bares SH
Am J Case Rep; 2020 Jun; 21():e923326. PubMed ID: 32493896
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S
J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
